PT  - JOURNAL ARTICLE
AU  - Moreews, Marion
AU  - Le Gouge, Kenz
AU  - Bellomo, Alicia
AU  - Malcus, Christophe
AU  - Pescarmona, Rémi
AU  - Khaldi-Plassart, Samira
AU  - Djebali, Sophia
AU  - Mathieu, Anne-Laure
AU  - Perret, Magali
AU  - Villard, Marine
AU  - Chopin, Emilie
AU  - Rouvet, Isabelle
AU  - Vandenesh, Francois
AU  - Dupieux, Céline
AU  - Pouyau, Robin
AU  - Teyssedre, Sonia
AU  - Guerder, Margaux
AU  - Louazon, Tiphaine
AU  - Anne-Moulin-Zinsch,
AU  - Duperril, Marie
AU  - Patural, Hugues
AU  - Giovannini-Chami, Lisa
AU  - Portefaix, Aurélie
AU  - Kassai, Behrouz
AU  - Venet, Fabienne
AU  - Monneret, Guillaume
AU  - Lombard, Christine
AU  - Flodrops, Hugues
AU  - Bastard, Paul
AU  - Zhang, Shen-Ying
AU  - Dubois, Valérie
AU  - Thaunat, Olivier
AU  - Richard, Jean-Christophe
AU  - Mezidi, Mehdi
AU  - Abel, Laurent
AU  - Casanova, Jean Laurent
AU  - Marvel, Jacqueline
AU  - Trouillet-Assant, Sophie
AU  - Klatzmann, David
AU  - Walzer, Thierry
AU  - Dreux, Marlène
AU  - Mariotti-Ferrandiz, Encarnita
AU  - Javouhey, Etienne
AU  - Belot, Alexandre
TI  - Superantigenic TCR Vbeta 21.3 signature in Multisystem Inflammatory Syndrome in Children
AID  - 10.1101/2021.02.11.21251166
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.11.21251166
4099  - http://medrxiv.org/content/early/2021/02/12/2021.02.11.21251166.short
4100  - http://medrxiv.org/content/early/2021/02/12/2021.02.11.21251166.full
AB  - Objectives Multiple Inflammatory Syndrome in Children (MIS-C) is the most severe pediatric form of COVID-19 and occurs in previously healthy children. MIS-C combines features of Kawasaki disease and Toxic Shock Syndrome (TSS).Methods Children with suspected MIS-C were included within the first week of diagnosis and a large scale immunoassay was performed to determein the immunologic signature of these patients.Results We characterized the immunological profile of 27 MIS-C cases in comparison with 4 KD and 4 TSS cases. Similarly to TSS, an increase of serum inflammatory cytokines (IL-6, TNF-a, CD25s) was observed in MIS-C contrasting with low expression of HLA-DR monocytes, a feature often associated with immune paralysis. Expansions of T cells expressing the Vβ21.3 T cell receptor β chain variable region were detected in both CD4 and CD8 subsets in almost 50% of patients and Vβ21.3-positive T cells expressed high level of HLA-DR highlighting their specific activation. TCR sequencing uncovered the polyclonal nature of the Vβ 21.3+ population. SARS-CoV2 antigene-specific production of interferon gamma in T cells was not increased in MIS-C T cells compared to COVID-19 patients suggesting the antigen-specific immune response in MIS-C patients is not pivotal to the manifestation.Conclusions Our findings argue in favor of a strong activation of the immune system related to a superantigenic immune response in MIS-C with a specific polyclonal Vβ21.3 T cell expansion.Key messages What is already known about this subject ?MIS-C occurs 3-5 weeks after acute SARS-CoV2 infection and overlap features of Toxic Shock syndrome and Kawasaki disease.MIS-C appears different in term of cytokine and autoantibodies generation from KD with subtle signs of T cells activationWhat does this study add?This study demonstrates that Vβ21.3+ CD4 and CD8 T cells are highly increased in about 50% of MIS-C and distinctive of the Vβ2+ expansion observed in toxic shock syndrome in This reflects a specific T cell activation and cytokine release syndrome similar to toxic shock syndromeHow mich this impact on clinical practice or future developments?Vβ21.3+ signature can be available on a short term basis by flowcytometry and represents a signature of the MIS-C.As for TSS, immunomodulating therapies may revert the superantigenic activation and resolve this life threatening pediatric condition.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04376476Funding StatementFundings: This work was funded by Fondation Hospices Civils de Lyon.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:HPI COVID: Written informed consent was obtained for data collection and blood sampling relating to patients and healthy control subjects. The clinical study for children has been registered on ClinicalTrial.gov(NCT04376476) and approved by the national review board for biomedical research in April 2020 (Comite de Protection des Personnes Sud Mediterranee I, Marseille, France) (ID-RCB: 2020-A01102-37).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request